Aldeyra Therapeutics Inc. (ALDX) Stock Rating Reaffirmed by Cowen and Company
Aldeyra Therapeutics Inc. (NASDAQ:ALDX)‘s stock had its “buy” rating reiterated by equities researchers at Cowen and Company in a research note issued to investors on Tuesday.
Other equities analysts also recently issued research reports about the company. Zacks Investment Research upgraded Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research report on Tuesday, October 25th. HC Wainwright began coverage on Aldeyra Therapeutics in a research report on Monday, September 26th. They set a “buy” rating and a $18.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $14.30.
Shares of Aldeyra Therapeutics (NASDAQ:ALDX) opened at 6.35 on Tuesday. The firm’s 50-day moving average price is $6.58 and its 200-day moving average price is $6.05. The firm’s market capitalization is $39.66 million. Aldeyra Therapeutics has a 12 month low of $3.39 and a 12 month high of $8.19.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Monday, November 14th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.01. On average, equities analysts anticipate that Aldeyra Therapeutics will post ($1.69) earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in ALDX. Knoll Capital Management LP bought a new stake in Aldeyra Therapeutics during the third quarter worth approximately $1,038,000. Baker BROS. Advisors LP bought a new stake in Aldeyra Therapeutics during the third quarter worth approximately $1,110,000. Northern Trust Corp increased its stake in Aldeyra Therapeutics by 3.9% in the third quarter. Northern Trust Corp now owns 12,846 shares of the biotechnology company’s stock worth $100,000 after buying an additional 480 shares in the last quarter. Boxer Capital LLC increased its stake in Aldeyra Therapeutics by 361.2% in the second quarter. Boxer Capital LLC now owns 291,230 shares of the biotechnology company’s stock worth $1,657,000 after buying an additional 228,084 shares in the last quarter. Finally, Perceptive Advisors LLC increased its stake in Aldeyra Therapeutics by 56.4% in the second quarter. Perceptive Advisors LLC now owns 1,940,458 shares of the biotechnology company’s stock worth $11,041,000 after buying an additional 700,000 shares in the last quarter. Institutional investors and hedge funds own 51.01% of the company’s stock.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Stock Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related stocks with our FREE daily email newsletter.